Maria S Cortina1, Haydee E P Bazan. 1. Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, USA.
Abstract
PURPOSE OF REVIEW: To report recent data on the potential role of omega-3 fatty acids, in particular docosahexaenoic acid and its derivatives, in the treatment of dry eye syndrome. RECENT FINDINGS: Dietary supplementation with polyunsaturated fatty acids yields positive results in the improvement of dry eye signs and symptoms. Although several studies have shown this, evidence is still lacking as to which fatty acid or what combination constitutes the most effective treatment. Studies show that treatment with alpha-linoleic acid reduces dry eye-induced inflammation. Eicosapentaenoic acid and docosahexaenoic acid derivatives, particularly resolvin E1 (RvE1) and neuroprotectin D1, appear to be responsible for docosahexaenoic acid's anti-inflammatory effect. This is supported in a study in which topical RvE1 resulted in decreased inflammation in a mouse dry eye model. Topical administration of pigment epithelium-derived factor in combination with docosahexaenoic acid accelerates the regeneration of corneal nerves after their damage during corneal surgery, promoting the return of sensitivity and reducing the signs of dry eye. This combined treatment also reduces objective signs of dry eye, such as rose bengal staining. SUMMARY: No firm recommendations can be made regarding optimal dietary supplementation of essential fatty acids that benefit dry eye patients. On the basis of animal data and preliminary human studies, docosahexaenoic acid and its derivatives appear to be a safe, effective topical treatment for dry eye patients. This may result from their role in the resolution of inflammation and the regeneration of damaged corneal nerves.
PURPOSE OF REVIEW: To report recent data on the potential role of omega-3 fatty acids, in particular docosahexaenoic acid and its derivatives, in the treatment of dry eye syndrome. RECENT FINDINGS: Dietary supplementation with polyunsaturated fatty acids yields positive results in the improvement of dry eye signs and symptoms. Although several studies have shown this, evidence is still lacking as to which fatty acid or what combination constitutes the most effective treatment. Studies show that treatment with alpha-linoleic acid reduces dry eye-induced inflammation. Eicosapentaenoic acid and docosahexaenoic acid derivatives, particularly resolvin E1 (RvE1) and neuroprotectinD1, appear to be responsible for docosahexaenoic acid's anti-inflammatory effect. This is supported in a study in which topical RvE1 resulted in decreased inflammation in a mousedry eye model. Topical administration of pigment epithelium-derived factor in combination with docosahexaenoic acid accelerates the regeneration of corneal nerves after their damage during corneal surgery, promoting the return of sensitivity and reducing the signs of dry eye. This combined treatment also reduces objective signs of dry eye, such as rose bengal staining. SUMMARY: No firm recommendations can be made regarding optimal dietary supplementation of essential fatty acids that benefit dry eyepatients. On the basis of animal data and preliminary human studies, docosahexaenoic acid and its derivatives appear to be a safe, effective topical treatment for dry eyepatients. This may result from their role in the resolution of inflammation and the regeneration of damaged corneal nerves.
Authors: Pranab K Mukherjee; Victor L Marcheselli; Sebastian Barreiro; Jane Hu; Dean Bok; Nicolas G Bazan Journal: Proc Natl Acad Sci U S A Date: 2007-08-01 Impact factor: 11.205
Authors: Juana Gallar; Timo M T Tervo; Waldir Neira; Juha M Holopainen; Maria E Lamberg; Fernando Miñana; M Carmen Acosta; Carlos Belmonte Journal: Invest Ophthalmol Vis Sci Date: 2010-04-07 Impact factor: 4.799
Authors: Petra S Larmo; Riikka L Järvinen; Niko L Setälä; Baoru Yang; Matti H Viitanen; Janne R K Engblom; Raija L Tahvonen; Heikki P Kallio Journal: J Nutr Date: 2010-06-16 Impact factor: 4.798
Authors: M Soledad Cortina; Jiucheng He; Na Li; Nicolas G Bazan; Haydee E P Bazan Journal: Invest Ophthalmol Vis Sci Date: 2009-09-24 Impact factor: 4.799
Authors: Maria Soledad Cortina; Jiucheng He; Tiffany Russ; Nicolas G Bazan; Haydee E P Bazan Journal: Invest Ophthalmol Vis Sci Date: 2013-06-12 Impact factor: 4.799